Recreational use of an erectile dysfunction drug can be risky for some

May 26, 2005

Although the drugs used to treat Erectile Dysfunction, Sildenafil (Viagra), Tadalafil (Cialis) and Vardenafil (Levitra), have generally been proven safe, recreational use of these drugs is associated with higher risks of sexually-transmitted diseases (STD's), including HIV. In a study in the current issue of The American Journal of Medicine, researchers from the San Francisco Department of Public Health evaluated 14 studies of Sildenafil use among men who have sex with men (MSM).

Sildenafil users engaged in unprotected sex with partners of unknown HIV status from twice as often to almost six times as often as non-users. HIV-positive MSM were almost twice as likely to be diagnosed with an STD if they were also Sildenafil users and the newly HIV infected were 2.5 times as likely to be users.

Further complicating the situation, 54% of users mixed Sildenafil with other drugs to enhance the sexual experience. One study reported that 36% of all Sildenafil users combined its use with other drugs, including methamphetamines (23%), ecstasy (18%), poppers (15%), ketamine (11%), and GHB (8%). A study among MSM seeking STD clinic services in San Francisco found Sildenafil to be used concurrently with ecstasy (43%), methamphetamines (28%), and amyl nitrate (15%).

Writing in the article, Jeffrey D. Klausner, MD, MPH, suggests that "Focused action is needed to target this ongoing public health problem. Although the current evidence of association exists only for Sildenafil, likely due to the relatively recent approval of Tadalafil and Vardenafil, the needed action should focus on all three phosphodiesterase inhibitors (PDIs), as the observed associations with Sildenafil use most likely would occur with drugs of identical nature. The labeling for PDIs should be modified to warn users of an increased risk for STDs, including HIV infection. Educational programs, particularly among physicians, MSM, and methamphetamine users, should be implemented to increase awareness as to the use of these medications and their association with STDs, including HIV infection."

In an accompanying editorial, Joseph S. Alpert, MD, University of Arizona Health Sciences Center, Tucson, is concerned about the public health implications when Sildenafil and its relatives are abused or used recreationally with illegal drugs. He points to a recent article published in The Lancet in which investigators from Rockefeller University reported on a patient who presented with a new strain of HIV virus that was considerably more virulent and progressed more rapidly to AIDS than any HIV virus previously found. Dr Alpert writes that "This patient had been abusing both Sildenafil and methamphetamine. The question that immediately leaped to mind was: What effect did the combined abuse of these drugs have on the patient? Could this have resulted in the development of the highly virulent HIV mutant? Does this combination drug abuse increase the likelihood of STD transmission and/or the propensity for unsafe sex?" Dr. Alpert also questions whether the risk of STD and unsafe sex is also increased in male heterosexual patients who use Sildenafil. He points to the need for increased physician and patient education as well as further exploration of the multiple implications surrounding abuse of Sildenafil.
-end-
The study is reported in "Sildenafil Use, Sexual Risk Behavior, and Risk for Sexually Transmitted Diseases, including HIV Infection: a Review" by Sean Swearingen, BA and Jeffrey D. Klausner, MD, MPH. It appears with the editorial, "Viagra: The Risks of Recreational Use" by Joseph S. Alpert, MD, in The American Journal of Medicine, Volume 118, Number 6, published by Elsevier.

Elsevier Health Sciences

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.